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such strong opinions as Sirolimus – it is either loved or loathed. Ini-
tial concerns about side effects and the 2002 black box warning
from the Food and Drug Administration (FDA) regarding the risk
of hepatic artery thrombosis (HAT) meant that for many years,
Sirolimus was not used widely in liver transplantation. However,
recent data show that Sirolimus offers potential beneﬁt in speciﬁc
areas such as hepatocellular carcinoma (HCC) and hepatitis C virus
(HCV)-infected grafts, with acceptable risk to beneﬁt ratios. It’s
time to recognize that Sirolimus offers safe and effective immune
suppression following liver transplantation.
Sirolimus was initially approved for renal transplantation by
the FDA in 1999 and its’ use in liver transplantation was met with
high expectations. However based on the results of two multi-
center trials (Wyeth 211 and 220) Sirolimus was not approved
by the FDA for liver transplantation and instead, a black box
warning was placed on its use. Speciﬁcally the warning stated
Sirolimus ‘‘was associated with excess mortality and graft loss
in a study in de novo transplant patient’’ and ‘‘associated with
an increase in HAT; most cases of HAT occurred within 30 days
post transplantation and most led to graft loss or death’’ [1].
Unfortunately neither study has been submitted for peer review,
so the transplant community has been unable to review the data.
Contrary to general perception, these two trials contained
conﬂicting data, especially regarding the incidence of HAT. In
the ﬁrst trial (Wyeth 211) a study of 111 patients taking Siroli-
mus and Ciclosporin was compared with 52 Tacrolimus ‘con-
trols’; there was no statistical difference in HAT (9.0% vs. 3.8%,
p = 0.10), graft survival or patient survival and the incidence of
rejection was lower with Sirolimus [2]. The second study (Wyeth
220), which compared 110 patients taking Sirolimus and Tacrol-
imus with 112 Tacrolimus ‘controls’ was halted prematurely.
There was no statistical difference in HAT (5.5% vs. 0.9%,
p = 0.07) although there were higher rates of graft loss and death
[3]. These trials formed the basis of the black box warning regard-
ing HAT and survival, but neither trial showed that HAT occurred
at a higher rate than expected, while one showed signiﬁcantly
worse graft and patient survival with Sirolimus.
Since 2000 there have been 20 published reports of de novo
mTOR inhibitor use in liver transplantation and all have shown
either a reduced incidence of HAT with Sirolimus, or no difference
compared to controls [4–15]. Furthermore, all have shown either
improved, or similar, patient and graft survival with Sirolimus.Journal of Hepatology 20
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ing to the black box warning. In contrast, a large report of the
combined experience of 252 patients from the University of Col-
orado and University of Alberta described an HAT incidence of
1.2% in those receiving Sirolimus, which was signiﬁcantly lower
than in controls. The 1-year and 5-year patient survival of 92%
and 84% were statistically similar to controls [8]. This paralleled
our large experience from the Baylor Transplant Institute of 371
patients receiving de novo Sirolimus in liver transplantation,
which showed a signiﬁcantly lower incidence of HAT (1.1%) with
Sirolimus compared to controls. We went more than 11 years and
over 300 consecutive de novo Sirolimus-treated patients without
seeing HAT on Sirolimus. Additionally we found similar 1-year
and 5-year patient survival of 93% and 76% with Sirolimus [16].
While both studies are retrospective, when combined, the num-
ber of patients (more the 600) treated de novo with Sirolimus
dwarves the 221 patients in the trials used by the FDA and both
centers’ nearly identical experience validate their accuracy and
show that Sirolimus actually reduces the risk of HAT – the oppo-
site of what has been shown before.
Despite the black box warning, many centers have relied on
their long term experience with Sirolimus to assess its value.
Many experienced clinicians recognize the potential beneﬁt of
off-label Sirolimus use, since 12% of liver recipients in the United
States receive Sirolimus during the ﬁrst year. As with other
immunosuppressants, Sirolimus is associated with side effects;
these include hyperlipidemia, mouth ulcers, poor wound healing,
and hematological issues, but increased familiarity has made it
easier to manage side effects.
Hyperlipidemia is the most common side effect from Siroli-
mus affecting up to 45% of liver recipients and often cited as a
concern for patient safety [17]. The dyslipidemia can be con-
trolled with omega-3 fatty acids from ﬁsh oil and statins [18].
Despite the dyslipidemia, Sirolimus has not been shown to have
a negative impact on cardiovascular events; randomized studies
show that Sirolimus does not represent a risk factor for cardio-
vascular disease [19]. The reverse may in fact be true, since sev-
eral in vivo studies have demonstrated that Sirolimus reduces
atherosclerotic lesion formation. This suggests that even if Sirol-
imus-induced dyslipidemia is atherogenic, it is countered by the
anti-inﬂammatory and anti-proliferative effects of Sirolimus
[20–21].
The other side effects of Sirolimus are also managed easily.
Mouth ulcers were a common cause for discontinuation, but
treatment with topical kenalog-in-orobase eliminates pain and
heals the ulcer in 2–3 days without discontinuation. Poor wound12 vol. 56 j 285–287
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healing is also a concern, based on the role of the mTOR pathway
in ﬁbrosis. Some centers accommodate this concern by delaying
Sirolimus until 1–2 weeks after transplantation. We use Siroli-
mus immediately post-op and has not found a signiﬁcant prob-
lem with wound healing, although in larger, diabetic patients,
we use an incision-line wound vac on top of the staples, to
remove ﬂuid from the wound and pull the tissue together. If
major surgery is needed, Sirolimus can be replaced temporarily
with Mycophenolate for 3 weeks peri-operatively and patients
converted back post-operatively without incident. Hematological
issues such as thrombocytopenia and leukopenia have been
reported, although the large studies of Sirolimus use in liver
transplantation do not show any difference in the incidence of
hematological side effects [8]. Our experience found leukopenia
in 40% of patients, which was reversible over time. Despite the
leukopenia, there was no difference in bacterial and fungal infec-
tion, while viral infections such as CMV were reduced signiﬁ-
cantly on Sirolimus [4,16]. Pneumonitis, which affects 1–2% of
liver transplant patients and is characterized by diffuse bilateral
pulmonary inﬁltrates without a clear infectious etiology, repre-
sents the one side effect that requires discontinuation of
Sirolimus [22].
Recent studies have identiﬁed potential new beneﬁts from
using Sirolimus that alter the risk-beneﬁt ratios. mTOR inhibitors
are anti-neoplastic because of their anti-proliferative and anti-
angiogenic properties and they are now approved as anti-tumor
agents. For liver transplant recipients with hepatocellular carci-
nomas (HCC) three large studies have shown a signiﬁcant beneﬁ-
cial impact of Sirolimus on 5-year survival [4–6]. Comparing
Sirolimus with ‘control’ Chinnakotla et al. reported 5-year sur-
vival of 80% vs. 59%, Zimmerman et al. reported 80% vs. 62%,
and Toso et al. reported 83% vs. 68.7%, respectively. Toso sums
his study up succinctly, stating ‘‘twice as many recipients not
on Sirolimus died from cancer’’.
Renal dysfunction from long-term use of calcineurin inhibi-
tors (CNI) is a major concern and mTOR inhibitors avoid this mor-
bidity. Early studies of the impact of Sirolimus on post-transplant
renal function yielded mixed results because Sirolimus was not
given de novo or prescribed after renal dysfunction was already
established. The ﬁrst prospective randomized trial of de novo
mTOR inhibitor use in routine liver transplants showed improved
GFR and a signiﬁcantly lower incidence of advanced chronic kid-
ney disease, demonstrating that mTOR inhibitors can limit renal
dysfunction in liver transplantation [23].
More exciting beneﬁts from Sirolimus are being elucidated
and may change the ﬁeld of transplant. Recent data from our cen-
ter have shown that de novo Sirolimus reduces HCV related ﬁbro-
sis progression markedly when evaluated by annual protocol
biopsy and multivariate analysis showed Sirolimus to be the only
independent predictor of low ﬁbrosis stage post-transplant [24].
Since recurrent HCV is the major cause of allograft failure, this
could have a major impact on long-term allograft survival.
Another potential beneﬁt from Sirolimus use is the impact of
Sirolimus on weight gain in liver transplant recipients. Recent
data demonstrate that Sirolimus prevents characteristic post-
transplant weight gain, a major cause of morbidity [25].
Substantial evidence from many centers demonstrates that
concerns about HAT with de novo Sirolimus use are unwarranted.
Growing experience with Sirolimus has taught us how to manage
side effects. In light of this and with many of the beneﬁts from
Sirolimus suggesting a major impact on long-term patient and286 Journal of Hepatology 201graft survival for patients transplanted with HCC and HCV and
the potential for Sirolimus to limit signiﬁcant post-transplant
co-morbidity such as weight gain and renal dysfunction, it is
becoming difﬁcult to argue against its use in well deﬁned
populations.
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